15 May 2026
Since its establishment in 2010, MPP and its partners have contributed to a substantial increase in the number of people accessing quality-assured WHO-recommended essential medicines for infectious diseases, such as HIV. Today, in the wake of the most devastating pandemic in a century, with funding cuts in global health, rising mortality from non-communicable diseases and increased risk of health emergencies, the world finds itself once again at a crossroads.
MPP’s new ambitious five-year strategy, launched today, reflects MPP’s evolution in recent years to address these challenges. While we continue to support affordable access to essential medicines in low- and middle-income countries (LMICs) through licensing and technology transfer, we are also committed to supporting a more geographically diversified manufacturing ecosystem and a safer, more resilient global community, better prepared to respond to future health emergencies.
In the 16 years since its inception, MPP’s unique licensing model has helped to significantly advance access to essential health products. To date, 44 products have been licensed through MPP’s agreements with 22 innovators, resulting in 62.14 billion doses of treatment being supplied to 148 LMICs through MPP’s licensees.
MPP now seeks to build on these achievements with today’s official launch of its new Strategy 2026-2030. The new strategy coalesces around three key goals:
Goal 1: Catalyse affordable access to key quality-assured health products. MPP will focus on enabling broader, faster and more affordable access to innovative health products and technologies with strong potential for public health impact, including paediatric and long-acting formulations.
Goal 2: Advance diversified and sustainable manufacturing of health products and technologies. MPP will support the manufacturing of priority health products and technologies in LMICs, with a view to sustainability and affordability. This will include support for regional and local production ecosystems, and for companies’ capacity to manufacture key platform technologies.
Goal 3: Strengthen equitable health emergency preparedness and response. MPP’s focus will be on vaccines, therapeutics and diagnostics for emergency response to pandemic-prone pathogens, including influenza and other emerging threats. Technology platforms – such as the mRNA Technology Transfer Programme co-led by WHO and MPP – that support rapid adaptation and scale-up are a key element of this focus, as is collaboration with regional and global partners to maintain readiness and coordination.
Overall, between 2010 and 2030, 50 new health products will have been supplied in LMICs thanks to MPP’s public health-oriented voluntary licensing and technology transfer.
Commenting, MPP’s Executive Director Charles Gore said: “Our new strategy is built on 16 years of experience to ensure that people benefit from health innovations as quickly as possible, as equitably as possible, and as sustainably as possible. We will achieve this through partnerships and through our public health licensing and technology transfer. We are committed to ensuring over the next five years that our unique approach to turning innovation into access and access into impact gets a broader range of critical health products into the hands of more people who so badly need them.”
Marie-Paule Kieny, Chair of MPP’s Governance Board, said: “This new strategy reflects both the evolution of MPP and the changing global health landscape. Scientific innovation continues to accelerate, offering new opportunities, but also raising important questions about how quickly and equitably these innovations reach people in LMICs. MPP’s mission remains clear: to ensure timely, affordable and equitable access to essential medicines and other health technologies for all who need them.”
More information on our strategy
Download the full strategy document
Press and Media
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of innovative medicines and other health technologies for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders to prioritise and license needed health products and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 22 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, a post-partum haemorrhage medicine, three oral antiviral treatments for COVID-19 and 16 COVID-19 technologies.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC), Government of Canada and Coeffient Giving. MPP’s activities in technology transfer are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, the Government of Flanders and SDC.